

Greg Yothers

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6207467/publications.pdf>

Version: 2024-02-01

130
papers

19,136
citations

34105

52
h-index

19190

118
g-index

133
all docs

133
docs citations

133
times ranked

17058
citing authors

#	ARTICLE	IF	CITATIONS
1	Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer. <i>New England Journal of Medicine</i> , 2005, 353, 1673-1684.	27.0	4,956
2	Oxaliplatin Combined With Weekly Bolus Fluorouracil and Leucovorin As Surgical Adjuvant Chemotherapy for Stage II and III Colon Cancer: Results From NSABP C-07. <i>Journal of Clinical Oncology</i> , 2007, 25, 2198-2204.	1.6	955
3	Preoperative Multimodality Therapy Improves Disease-Free Survival in Patients With Carcinoma of the Rectum: NSABP R-03. <i>Journal of Clinical Oncology</i> , 2009, 27, 5124-5130.	1.6	796
4	Adjuvant Olaparib for Patients with <i>BRCA1</i> - or <i>BRCA2</i> -Mutated Breast Cancer. <i>New England Journal of Medicine</i> , 2021, 384, 2394-2405.	27.0	764
5	Assessment of Cardiac Dysfunction in a Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Paclitaxel, With or Without Trastuzumab As Adjuvant Therapy in Node-Positive, Human Epidermal Growth Factor Receptor 2 Overexpressing Breast Cancer: NSABP B-31. <i>Journal of Clinical Oncology</i> , 2005, 23, 7811-7819.	1.6	722
6	Paclitaxel After Doxorubicin Plus Cyclophosphamide As Adjuvant Chemotherapy for Node-Positive Breast Cancer: Results From NSABP B-28. <i>Journal of Clinical Oncology</i> , 2005, 23, 3686-3696.	1.6	585
7	Oxaliplatin As Adjuvant Therapy for Colon Cancer: Updated Results of NSABP C-07 Trial, Including Survival and Subset Analyses. <i>Journal of Clinical Oncology</i> , 2011, 29, 3768-3774.	1.6	560
8	Phase III Trial Assessing Bevacizumab in Stages II and III Carcinoma of the Colon: Results of NSABP Protocol C-08. <i>Journal of Clinical Oncology</i> , 2011, 29, 11-16.	1.6	551
9	Evidence for Cure by Adjuvant Therapy in Colon Cancer: Observations Based on Individual Patient Data From 20,898 Patients on 18 Randomized Trials. <i>Journal of Clinical Oncology</i> , 2009, 27, 872-877.	1.6	539
10	DNA Mismatch Repair Status and Colon Cancer Recurrence and Survival in Clinical Trials of 5-Fluorouracil-Based Adjuvant Therapy. <i>Journal of the National Cancer Institute</i> , 2011, 103, 863-875.	6.3	469
11	Real-World Performance of HER2 Testing--National Surgical Adjuvant Breast and Bowel Project Experience. <i>Journal of the National Cancer Institute</i> , 2002, 94, 852-854.	6.3	463
12	Seven-Year Follow-Up Assessment of Cardiac Function in NSABP B-31, a Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Paclitaxel (ACP) With ACP Plus Trastuzumab As Adjuvant Therapy for Patients With Node-Positive, Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer. <i>Journal of Clinical Oncology</i> , 2012, 30, 3792-3799.	1.6	446
13	CDX2 as a Prognostic Biomarker in Stage II and Stage III Colon Cancer. <i>New England Journal of Medicine</i> , 2016, 374, 211-222.	27.0	388
14	Capecitabine and Oxaliplatin in the Preoperative Multimodality Treatment of Rectal Cancer: Surgical End Points From National Surgical Adjuvant Breast and Bowel Project Trial R-04. <i>Journal of Clinical Oncology</i> , 2014, 32, 1927-1934.	1.6	373
15	Body Mass Index and Outcomes in Patients Who Receive Adjuvant Chemotherapy for Colon Cancer. <i>Journal of the National Cancer Institute</i> , 2006, 98, 1647-1654.	6.3	317
16	Oral Uracil and Tegafur Plus Leucovorin Compared With Intravenous Fluorouracil and Leucovorin in Stage II and III Carcinoma of the Colon: Results From National Surgical Adjuvant Breast and Bowel Project Protocol C-06. <i>Journal of Clinical Oncology</i> , 2006, 24, 2059-2064.	1.6	297
17	Mutation Profiling and Microsatellite Instability in Stage II and III Colon Cancer: An Assessment of Their Prognostic and Oxaliplatin Predictive Value. <i>Clinical Cancer Research</i> , 2012, 18, 6531-6541.	7.0	272
18	Relationship Between Tumor Gene Expression and Recurrence in Four Independent Studies of Patients With Stage II/III Colon Cancer Treated With Surgery Alone or Surgery Plus Adjuvant Fluorouracil Plus Leucovorin. <i>Journal of Clinical Oncology</i> , 2010, 28, 3937-3944.	1.6	271

#	ARTICLE	IF	CITATIONS
19	HER2 and Choice of Adjuvant Chemotherapy for Invasive Breast Cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-15. <i>Journal of the National Cancer Institute</i> , 2000, 92, 1991-1998.	6.3	258
20	Initial Safety Report of NSABP C-08: A Randomized Phase III Study of Modified FOLFOX6 With or Without Bevacizumab for the Adjuvant Treatment of Patients With Stage II or III Colon Cancer. <i>Journal of Clinical Oncology</i> , 2009, 27, 3385-3390.	1.6	244
21	Neoadjuvant 5-FU or Capecitabine Plus Radiation With or Without Oxaliplatin in Rectal Cancer Patients: A Phase III Randomized Clinical Trial. <i>Journal of the National Cancer Institute</i> , 2015, 107, djv248.	6.3	242
22	National Institutes of Health State-of-the-Science Conference Statement: Diagnosis and Management of Ductal Carcinoma In Situ September 22-24, 2009. <i>Journal of the National Cancer Institute</i> , 2010, 102, 161-169.	6.3	224
23	Anthracyclines in Early Breast Cancer: The ABC Trials—USOR 06-090, NSABP B-46-I/USOR 07132, and NSABP B-49 (NRG Oncology). <i>Journal of Clinical Oncology</i> , 2017, 35, 2647-2655.	1.6	223
24	End Points for Colon Cancer Adjuvant Trials: Observations and Recommendations Based on Individual Patient Data From 20,898 Patients Enrolled Onto 18 Randomized Trials From the ACCENT Group. <i>Journal of Clinical Oncology</i> , 2007, 25, 4569-4574.	1.6	220
25	ctDNA applications and integration in colorectal cancer: an NCI Colon and Rectal—Anal Task Forces whitepaper. <i>Nature Reviews Clinical Oncology</i> , 2020, 17, 757-770.	27.6	218
26	Impact of Age on the Efficacy of Newer Adjuvant Therapies in Patients With Stage II/III Colon Cancer: Findings From the ACCENT Database. <i>Journal of Clinical Oncology</i> , 2013, 31, 2600-2606.	1.6	211
27	Bevacizumab in Stage II-III Colon Cancer: 5-Year Update of the National Surgical Adjuvant Breast and Bowel Project C-08 Trial. <i>Journal of Clinical Oncology</i> , 2013, 31, 359-364.	1.6	187
28	Validation of the 12-Gene Colon Cancer Recurrence Score in NSABP C-07 As a Predictor of Recurrence in Patients With Stage II and III Colon Cancer Treated With Fluorouracil and Leucovorin (FU/LV) and FU/LV Plus Oxaliplatin. <i>Journal of Clinical Oncology</i> , 2013, 31, 4512-4519.	1.6	155
29	Primary mFOLFOX6 Plus Bevacizumab Without Resection of the Primary Tumor for Patients Presenting With Surgically Unresectable Metastatic Colon Cancer and an Intact Asymptomatic Colon Cancer: Definitive Analysis of NSABP Trial C-10. <i>Journal of Clinical Oncology</i> , 2012, 30, 3223-3228.	1.6	145
30	Body mass index at diagnosis and survival among colon cancer patients enrolled in clinical trials of adjuvant chemotherapy. <i>Cancer</i> , 2013, 119, 1528-1536.	4.1	141
31	Clinical Outcome From Oxaliplatin Treatment in Stage II/III Colon Cancer According to Intrinsic Subtypes. <i>JAMA Oncology</i> , 2016, 2, 1162.	7.1	140
32	Effect of adjuvant capecitabine or fluorouracil, with or without oxaliplatin, on survival outcomes in stage III colon cancer and the effect of oxaliplatin on post-relapse survival: a pooled analysis of individual patient data from four randomised controlled trials. <i>Lancet Oncology</i> , The, 2014, 15, 1481-1492.	10.7	139
33	Impact of Patient Factors on Recurrence Risk and Time Dependency of Oxaliplatin Benefit in Patients With Colon Cancer: Analysis From Modern-Era Adjuvant Studies in the Adjuvant Colon Cancer End Points (ACCENT) Database. <i>Journal of Clinical Oncology</i> , 2016, 34, 843-853.	1.6	128
34	Long-Term Survival Results of Surgery Alone Versus Surgery Plus 5-Fluorouracil and Leucovorin for Stage II and Stage III Colon Cancer: Pooled Analysis of NSABP C-01 Through C-05. A Baseline from Which to Compare Modern Adjuvant Trials. <i>Annals of Surgical Oncology</i> , 2010, 17, 959-966.	1.5	117
35	Neoadjuvant Rectal (NAR) Score: a New Surrogate Endpoint in Rectal Cancer Clinical Trials. <i>Current Colorectal Cancer Reports</i> , 2015, 11, 275-280.	0.5	115
36	Multinational study of pneumococcal serotypes causing acute otitis media in children. <i>Pediatric Infectious Disease Journal</i> , 2002, 21, 1008-1016.	2.0	114

#	ARTICLE	IF	CITATIONS
37	Impact of age and medical comorbidity on adjuvant treatment outcomes for stage III colon cancer: a pooled analysis of individual patient data from four randomized, controlled trials. <i>Annals of Oncology</i> , 2015, 26, 715-724.	1.2	104
38	Prognosis of microsatellite instability and/or mismatch repair deficiency stage III colon cancer patients after disease recurrence following adjuvant treatment: results of an ACCENT pooled analysis of seven studies. <i>Annals of Oncology</i> , 2019, 30, 1466-1471.	1.2	97
39	Conditional Survival and the Choice of Conditioning Set for Patients With Colon Cancer: An Analysis of NSABP Trials C-03 Through C-07. <i>Journal of Clinical Oncology</i> , 2010, 28, 2544-2548.	1.6	87
40	Microsatellite Instability in Patients With Stage III Colon Cancer Receiving Fluoropyrimidine With or Without Oxaliplatin: An ACCENT Pooled Analysis of 12 Adjuvant Trials. <i>Journal of Clinical Oncology</i> , 2021, 39, 642-651.	1.6	84
41	Association of DNA Mismatch Repair and Mutations in <i>BRAF</i> and <i>KRAS</i> With Survival After Recurrence in Stage III Colon Cancers. <i>JAMA Oncology</i> , 2017, 3, 472.	7.1	82
42	Use of Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer. <i>JAMA Oncology</i> , 2021, 7, 1225.	7.1	82
43	Long-term neurotoxicity effects of oxaliplatin added to fluorouracil and leucovorin as adjuvant therapy for colon cancer: Results from National Surgical Adjuvant Breast and Bowel Project trials C-07 and LTS-01. <i>Cancer</i> , 2012, 118, 5614-5622.	4.1	76
44	Association Between Disease-Free Survival and Overall Survival When Survival Is Prolonged After Recurrence in Patients Receiving Cytotoxic Adjuvant Therapy for Colon Cancer: Simulations Based on the 20,800 Patient ACCENT Data Set. <i>Journal of Clinical Oncology</i> , 2010, 28, 460-465.	1.6	67
45	End Points in Advanced Colon Cancer Clinical Trials: A Review and Proposal. <i>Journal of Clinical Oncology</i> , 2007, 25, 3572-3575.	1.6	66
46	Comparison of Outcomes After Fluorouracil-Based Adjuvant Therapy for Stages II and III Colon Cancer Between 1978 to 1995 and 1996 to 2007: Evidence of Stage Migration From the ACCENT Database. <i>Journal of Clinical Oncology</i> , 2013, 31, 3656-3663.	1.6	65
47	ACCENT-Based Web Calculators to Predict Recurrence and Overall Survival in Stage III Colon Cancer. <i>Journal of the National Cancer Institute</i> , 2014, 106, .	6.3	62
48	Health-Related Quality of Life in Axillary Node-Negative, Estrogen Receptor-Negative Breast Cancer Patients Undergoing AC Versus CMF Chemotherapy: Findings from the National Surgical Adjuvant Breast and Bowel Project B-23. <i>Breast Cancer Research and Treatment</i> , 2004, 86, 153-164.	2.5	61
49	Outcomes Among Black Patients With Stage II and III Colon Cancer Receiving Chemotherapy: An Analysis of ACCENT Adjuvant Trials. <i>Journal of the National Cancer Institute</i> , 2011, 103, 1498-1506.	6.3	61
50	Quality of Life in Operable Colon Cancer Patients Receiving Oral Compared With Intravenous Chemotherapy: Results From National Surgical Adjuvant Breast and Bowel Project Trial C-06. <i>Journal of Clinical Oncology</i> , 2007, 25, 424-430.	1.6	60
51	FOLFOX and FLOX Regimens for the Adjuvant Treatment of Resected Stage II and III Colon Cancer. <i>Cancer Investigation</i> , 2008, 26, 956-963.	1.3	58
52	Defective Mismatch Repair and Benefit from Bevacizumab for Colon Cancer: Findings from NSABP C-08. <i>Journal of the National Cancer Institute</i> , 2013, 105, 989-992.	6.3	56
53	Prognostic impact of deficient mismatch repair (dMMR) in 7,803 stage II/III colon cancer (CC) patients (pts): A pooled individual pt data analysis of 17 adjuvant trials in the ACCENT database.. <i>Journal of Clinical Oncology</i> , 2014, 32, 3507-3507.	1.6	53
54	Association of Obesity With DNA Mismatch Repair Status and Clinical Outcome in Patients With Stage II or III Colon Carcinoma Participating in NCCTG and NSABP Adjuvant Chemotherapy Trials. <i>Journal of Clinical Oncology</i> , 2012, 30, 406-412.	1.6	51

#	ARTICLE	IF	CITATIONS
55	Comparative Effectiveness of Sphincter-Sparing Surgery Versus Abdominoperineal Resection in Rectal Cancer. <i>Annals of Surgery</i> , 2015, 261, 144-148.	4.2	50
56	Biomarker discovery for colon cancer using a 761 gene RT-PCR assay. <i>BMC Genomics</i> , 2007, 8, 279.	2.8	46
57	Cancer survivorship research: the challenge of recruiting adult long term cancer survivors from a cooperative clinical trials group. <i>Journal of Cancer Survivorship</i> , 2009, 3, 137-147.	2.9	44
58	Sex and Adverse Events of Adjuvant Chemotherapy in Colon Cancer: An Analysis of 34,640 Patients in the ACCENT Database. <i>Journal of the National Cancer Institute</i> , 2021, 113, 400-407.	6.3	44
59	Severe enteropathy among patients with stage II/III colon cancer treated on a randomized trial of bolus 5-fluorouracil/leucovorin plus or minus oxaliplatin. <i>Cancer</i> , 2007, 110, 1945-1950.	4.1	42
60	Toward Progression-Free Survival As a Primary End Point in Advanced Colorectal Cancer. <i>Journal of Clinical Oncology</i> , 2007, 25, 5153-5154.	1.6	34
61	Benefits and Adverse Events in Younger Versus Older Patients Receiving Adjuvant Chemotherapy for Colon Cancer: Findings From the Adjuvant Colon Cancer Endpoints Data Set. <i>Journal of Clinical Oncology</i> , 2012, 30, 2334-2339.	1.6	34
62	Determinants of Early Mortality Among 37,568 Patients With Colon Cancer Who Participated in 25 Clinical Trials From the Adjuvant Colon Cancer Endpoints Database. <i>Journal of Clinical Oncology</i> , 2016, 34, 1182-1189.	1.6	32
63	Exploring and validating surrogate endpoints in colorectal cancer. <i>Lifetime Data Analysis</i> , 2008, 14, 54-64.	0.9	30
64	Quality of life and symptoms in long-term survivors of colorectal cancer: results from NSABP protocol LTS-01. <i>Journal of Cancer Survivorship</i> , 2017, 11, 111-118.	2.9	30
65	NIH state-of-the-science conference statement: diagnosis and management of ductal carcinoma in situ (DCIS). <i>NIH Consensus and State-of-the-science Statements</i> , 2009, 26, 1-27.	7.0	30
66	A method for utilizing co-primary efficacy outcome measures to screen regimens for activity in two-stage Phase II clinical trials. <i>Clinical Trials</i> , 2012, 9, 385-395.	1.6	27
67	The Predictive and Prognostic Value of Sex in Early-Stage Colon Cancer: A Pooled Analysis of 33,345 Patients from the ACCENT Database. <i>Clinical Colorectal Cancer</i> , 2013, 12, 179-187.	2.3	27
68	Surrogate endpoint validation: statistical elegance versus clinical relevance. <i>Statistical Methods in Medical Research</i> , 2008, 17, 477-486.	1.5	26
69	OlympiA: A phase III, multicenter, randomized, placebo-controlled trial of adjuvant olaparib after (neo)adjuvant chemotherapy in patients with germline BRCA1/2 mutations and high-risk HER2-negative early breast cancer. <i>Journal of Clinical Oncology</i> , 2021, 39, LBA1-LBA1.	1.6	26
70	NRG-GI002: A phase II clinical trial platform using total neoadjuvant therapy (TNT) in locally advanced rectal cancer (LARC) – First experimental arm (EA) initial results. <i>Journal of Clinical Oncology</i> , 2019, 37, 3505-3505.	1.6	26
71	Clinicopathological and Molecular Characteristics of Early-Onset Stage III Colon Adenocarcinoma: An Analysis of the ACCENT Database. <i>Journal of the National Cancer Institute</i> , 2021, 113, 1693-1704.	6.3	25
72	Colon Cancer Mutation: Prognosis/Prediction – Response. <i>Clinical Cancer Research</i> , 2013, 19, 1301-1301.	7.0	24

#	ARTICLE	IF	CITATIONS
73	Evaluating Treatment Tolerability in Cancer Clinical Trials Using the Toxicity Index. Journal of the National Cancer Institute, 2020, 112, 1266-1274.	6.3	24
74	Evaluation of the change of outcomes over a 10-year period in patients with stage III colon cancer: pooled analysis of 6501 patients treated with fluorouracil, leucovorin, and oxaliplatin in the ACCENT database. Annals of Oncology, 2020, 31, 480-486.	1.2	23
75	Tumour sidedness and intrinsic subtypes in patients with stage II/III colon cancer: analysis of NSABP C-07 (NRG Oncology). British Journal of Cancer, 2018, 118, 629-633.	6.4	18
76	Innovative estimation of survival using log-normal survival modelling on ACCENT database. British Journal of Cancer, 2013, 108, 784-790.	6.4	17
77	NRG-GI002: A phase II clinical trial platform using total neoadjuvant therapy (TNT) in locally advanced rectal cancer (LARC)â€™Pembrolizumab experimental arm (EA) primary results.. Journal of Clinical Oncology, 2021, 39, 8-8.	1.6	17
78	Neoadjuvant rectal cancer (RC) score to predict survival: Potential surrogate endpoint for early phase trials.. Journal of Clinical Oncology, 2014, 32, 3533-3533.	1.6	17
79	Guidelines for time-to-event end-point definitions in adjuvant randomised trials for patients with localised colon cancer: Results of the DATECAN initiative. European Journal of Cancer, 2020, 130, 63-71.	2.8	15
80	Routine Preventive Care and Cancer Surveillance in Long-Term Survivors of Colorectal Cancer: Results From National Surgical Adjuvant Breast and Bowel Project Protocol LTS-01. Journal of Clinical Oncology, 2010, 28, 5274-5279.	1.6	14
81	On the properties of the toxicity index and its statistical efficiency. Statistics in Medicine, 2021, 40, 1535-1552.	1.6	13
82	Interim joint analysis of the ABC (anthracyclines in early breast cancer) phase III trials (USOR 06-090,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf anthracycline/taxane-based chemotherapy regimens (TaxAC) in women with high-risk, HER2-negative breast cancer.. Journal of Clinical Oncology, 2016, 34, 1000-1000.	1.6	12
83	NRG-GI005 (COBRA): Phase II/III study of circulating tumor DNA as a predictive biomarker in adjuvant chemotherapy in patients with stage II colon cancer.. Journal of Clinical Oncology, 2020, 38, TPS261-TPS261.	1.6	12
84	Survival following early-stage colon cancer: an ACCENT-based comparison of patients versus a matched international general population. Annals of Oncology, 2015, 26, 950-958.	1.2	11
85	Predictive validity of NeoAdjuvant Rectal (NAR) Score and pathologic complete response (ypCR) for overall survival (OS) as surrogate endpoints in rectal cancer clinical trial.. Journal of Clinical Oncology, 2016, 34, 3533-3533.	1.6	10
86	Validity of Adjuvant! Online in older patients with stage III colon cancer based on 2967 patients from the ACCENT database. Journal of Geriatric Oncology, 2016, 7, 422-429.	1.0	9
87	Phase II study of durvalumab following neoadjuvant chemoRT in operable rectal cancer: NSABP FR-2.. Journal of Clinical Oncology, 2022, 40, 99-99.	1.6	8
88	Using cure models and multiple imputation to utilize recurrence as an auxiliary variable for overall survival. Clinical Trials, 2011, 8, 581-590.	1.6	7
89	Genetic Variant Associated With Survival of Patients With Stage II-III Colon Cancer. Clinical Gastroenterology and Hepatology, 2020, 18, 2717-2723.e3.	4.4	7
90	Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) Study: A randomized phase III study of atezolizumab (atezo) monotherapy versus mFOLFOX6/bevacizumab/atezo in the first-line treatment of patients (pts) with deficient DNA mismatch repair (dMMR) or microsatellite instability high (MSI-H) metastatic colorectal cancer (mCRC)â€™NRG-GI004/SWOG-S1610.. Journal of Clinical Oncology, 2021, 39, TPS3618-TPS3618.	1.6	6

#	ARTICLE	IF	CITATIONS
91	Toxicity Index, Patient-Reported Outcomes, and Early Discontinuation of Endocrine Therapy for Breast Cancer Risk Reduction in NRG Oncology/NSABP B-35. <i>Journal of Clinical Oncology</i> , 2021, 39, 3800-3812.	1.6	6
92	Cancer Hallmark-Based Gene Sets and Personalized Medicine for Patients With Stage II Colon Cancer. <i>JAMA Oncology</i> , 2016, 2, 23.	7.1	5
93	Benefit of Oxaliplatin in Stage III Colon Cancer According to IDEA Risk Groups: Findings from the ACCENT Database of 4934 Patients. <i>Clinical Colorectal Cancer</i> , 2021, 20, 130-136.	2.3	5
94	Reevaluating Disease-Free Survival as an Endpoint vs Overall Survival in Stage III Adjuvant Colon Cancer Trials. <i>Journal of the National Cancer Institute</i> , 2022, 114, 60-67.	6.3	5
95	Assessing the Quality of Rectal Cancer Pathology Reports in National Surgical Adjuvant Breast and Bowel Project Protocol R-04/NRG Oncology. <i>Diseases of the Colon and Rectum</i> , 2020, 63, 1063-1070.	1.3	4
96	A randomized phase III study of mFOLFOX6/bevacizumab combination chemotherapy with or without atezolizumab or atezolizumab monotherapy in the first-line treatment of patients (pts) with deficient DNA mismatch repair (dMMR) metastatic colorectal cancer (mCRC): Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) study (NRG-GI004/SWOG-S1610).. <i>Journal of Clinical Oncology</i> , 2020, 38, TPS260-TPS260.	1.6	4
97	NRG-GI008: Colon adjuvant chemotherapy based on evaluation of residual disease (CIRCULATE-US).. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS212-TPS212.	1.6	4
98	Simultaneous confidence band for the difference of segmented linear models. <i>Journal of Statistical Planning and Inference</i> , 2011, 141, 1059-1068.	0.6	3
99	Report from the SWOG Radiation Oncology Committee: Research Objectives Workshop 2017. <i>Clinical Cancer Research</i> , 2018, 24, 3500-3509.	7.0	3
100	A phase II clinical trial platform utilizing total neoadjuvant therapy (TNT) in rectal cancer: Nrg-GI002.. <i>Journal of Clinical Oncology</i> , 2016, 34, TPS3638-TPS3638.	1.6	3
101	Phase II/III study of circulating tumor DNA as a predictive biomarker in adjuvant chemotherapy in patients with stage II colon cancer: NRG-GI005 (COBRA).. <i>Journal of Clinical Oncology</i> , 2020, 38, TPS4121-TPS4121.	1.6	3
102	NRG-GI004/SWOG-S1610: Colorectal cancer metastatic dMMR immuno-therapy (COMMIT) study—A randomized phase III study of atezolizumab (atezo) monotherapy versus mFOLFOX6/bevacizumab/atezo in the first-line treatment of patients (pts) with deficient DNA mismatch repair (dMMR) or microsatellite instability high (MSI-H) metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS232-TPS232.	1.6	3
103	Randomization in Phase II Clinical Trials. <i>Clinical Advances in Hematology and Oncology</i> , 2006, 4, 776-8.	0.3	3
104	Health-related quality of life outcomes after neoadjuvant chemoradiotherapy for rectal cancer in NRG Oncology/NSABP Q4. <i>Cancer</i> , 2022, 128, 3233-3242.	4.1	3
105	Projecting Event-Based Analysis Dates in Clinical Trials: An Illustration Based on the International Duration Evaluation of Adjuvant Chemotherapy (IDEA) Collaboration. <i>Projecting Analysis Dates for the IDEA Collaboration</i> . <i>Forum of Clinical Oncology</i> , 2014, 5, 1-7.	0.2	2
106	Phase II/III study of circulating tumor DNA as a predictive biomarker in adjuvant chemotherapy in patients with stage II colon cancer:NRG-GI005 (COBRA).. <i>Journal of Clinical Oncology</i> , 2021, 39, TPS148-TPS148.	1.6	2
107	NRG-GI004/SWOG-S1610: Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) Study—A randomized phase III study of atezolizumab (atezo) monotherapy versus mFOLFOX6/bevacizumab/atezo in the first-line treatment of patients (pts) with deficient DNA mismatch repair (dMMR) or microsatellite instability high (MSI-H) metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , 2021, 39, TPS158-TPS158.	1.6	2
108	Abstract OT2-02-03: NSABP FB-13: An assessment of the biological and clinical effects of palbociclib with ovarian suppression and letrozole in the neoadjuvant treatment of pts (pts) with premenopausal (preM) estrogen-receptor positive/HER2-negative primary breast cancer. , 2020, , .		2

#	ARTICLE	IF	CITATIONS
109	Utilizing total neoadjuvant therapy (TNT) in rectal cancer: NRG-GI002, a phase II clinical trial platform.. Journal of Clinical Oncology, 2017, 35, TPS814-TPS814.	1.6	2
110	Genome-wide association with survival in stage II-III colon cancer clinical trials (NCCTG N0147,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 70 2018, 36, 3582-3582.	1.6	2
111	NSABP FR-2: Phase II study of durvalumab following neoadjuvant chemoRT in stage II-IV rectal cancer.. Journal of Clinical Oncology, 2020, 38, TPS264-TPS264.	1.6	2
112	Visualizing adverse events in clinical trials using correspondence analysis with R-package visae. BMC Medical Research Methodology, 2021, 21, 244.	3.1	2
113	Multiagent Regimens for Metastatic Colorectal Cancer: If Some Is Good, More Must Be Better. Journal of the National Cancer Institute, 2011, 103, 4-5.	6.3	1
114	Genetic Predictors of Severe Skin Toxicity in Patients with Stage III Colon Cancer Treated with Cetuximab: NCCTG N0147 (Alliance). Cancer Epidemiology Biomarkers and Prevention, 2021, 30, 404-411.	2.5	1
115	Phase II/III study of Circulating tumor DNA as a predictive Biomarker in Adjuvant chemotherapy in patients with stage II colon cancer: NRG-GI005 (COBRA).. Journal of Clinical Oncology, 2021, 39, TPS3622-TPS3622.	1.6	1
116	Clinical outcome and benefit of oxaliplatin in colon cancer according to intrinsic subtypes: Results from NRG Oncology/NSABP C-07.. Journal of Clinical Oncology, 2016, 34, 3510-3510.	1.6	1
117	Prognosis of microsatellite instability and/or mismatch repair deficiency stage III colon cancer patients after disease recurrence: Results of an accent meta-analysis of seven studies.. Journal of Clinical Oncology, 2019, 37, 3525-3525.	1.6	1
118	Phase II study of durvalumab following neoadjuvant chemoRT in stage II-IV rectal cancer: NSABP FR-2.. Journal of Clinical Oncology, 2019, 37, TPS3620-TPS3620.	1.6	1
119	Clinicopathological and molecular biological characteristics of early-onset stage II/III colorectal adenocarcinoma: An analysis of 25 studies with 47,184 patients (pts) in the adjuvant colon cancer end points (ACCENT) database.. Journal of Clinical Oncology, 2020, 38, 4099-4099.	1.6	1
120	Phase II/III study of circulating tumor DNA as a predictive biomarker in adjuvant chemotherapy in patients with stage II colon cancer: NRG-GI005 (COBRA).. Journal of Clinical Oncology, 2022, 40, TPS233-TPS233.	1.6	1
121	Patient-specific meta-analysis of 12-gene colon cancer recurrence score validation studies for recurrence risk assessment after surgery with or without 5FU and oxaliplatin. Journal of Gastrointestinal Oncology, 2022, 13, 126-136.	1.4	1
122	A Statistical Method for Association Analysis of Cell Type Compositions. Statistics in Biosciences, 2021, 13, 373-385.	1.2	0
123	Examination of the tumor immune microenvironment (TIME) with multispectral immunofluorescence (m-IF): Association of markers with prognosis and bevacizumab (bev) benefit in NRG Oncology/NSABP C-08.. Journal of Clinical Oncology, 2021, 39, 3516-3516.	1.6	0
124	Clinicopathological and molecular characteristics of early-onset stage III colon adenocarcinoma: An analysis of 25 studies with 35,713 patients in the Adjuvant Colon Cancer End Points (ACCENT) database.. Journal of Clinical Oncology, 2021, 39, 3597-3597.	1.6	0
125	Patient-specific meta-analysis of 3 validation studies of the 12-gene colon cancer recurrence score assay for recurrence risk assessment after surgery with or without 5FU and oxaliplatin.. Journal of Clinical Oncology, 2021, 39, 3599-3599.	1.6	0
126	Validity of Adjuvant! Online in elderly patients with stage III colon cancer based on 2,794 patients from the ACCENT database.. Journal of Clinical Oncology, 2016, 34, 3620-3620.	1.6	0

#	ARTICLE	IF	CITATIONS
127	Analysis of circulating tumour DNA for early relapse detection in stage III colorectal cancer after adjuvant chemotherapy. <i>Annals of Oncology</i> , 2019, 30, v52.	1.2	0
128	Benefit of oxaliplatin in stage III colon cancer according to IDEA risk groups: Analysis of MOSAIC and C-07 trials.. <i>Journal of Clinical Oncology</i> , 2020, 38, 118-118.	1.6	0
129	NSABP FC-10: Phase IB study of pembrolizumab in combination with premetrexed + oaliplatin in patients (pts) with chemo-refractory metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , 2020, 38, TPS262-TPS262.	1.6	0
130	Association of multiplex-immunofluorescence (m-IF) and gene expression signature with prognosis and bevacizumab (bev) treatment outcomes in NRG oncology/NSABP C-08: Implications for combining immune checkpoint blockade (ICB) and bev.. <i>Journal of Clinical Oncology</i> , 2022, 40, 140-140.	1.6	0